Omni Eye Services, a leading provider of ophthalmologic services at five locations in New York and New Jersey, today announced that Dr. Katherine M Mastrota, Center Director of Omni Eye Surgery in New York City, has written a treatment update for Contact Lenses Today describing a promising "new option for managing lid disease."
As Dr. Mastrota wrote in the August 10, 2014 issue of Contact Lenses Today, NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY) has begun marketing a product called i-Lid™ Cleanser, "a prescription only, eyelid and lash product which has shown significant anti-biofilm, anti-toxin and anti-microbial activity in vitro."
In eye care, ophthalmologists and optometrists have increasingly been using i-Lid Cleanser to use in the treatment regime for such conditions as blepharitis, where Staphylcocci bacteria grow on eyelids, causing swelling, redness, inflammation, irritation and a crusty build-up in millions of Americans. Patients who've had blepharitis for years report that i-Lid Cleanser has finally brought relief from the often-painful condition. Lab tests also show that, in addition to killing bacteria, i-Lid Cleanser neutralizes the toxins produced by bacteria. This makes it potentially useful as part of the treatment regime for dry eye syndrome, which typically results when Staphylcocci growing on the lid surface secrete toxins causing the meibomian glands to be obstructed. With a product like i-Lid Cleanser, "a great opportunity exists to improve the management of lid disease and I look forward to gaining experience with this product," wrote Dr. Mastrota.
Contact Lenses Today is a weekly newsletter published by Contact Lens Spectrum, a key source of clinical information about the use of contact lenses and the treatment of eye conditions.
In addition to directing eye surgery at Omni Eye Services' New York City location, Dr. Mastrota is a Contributing Editor to Contact Lens Spectrum and the online newsletter, Optometric Physician. She sits on the Editorial Board of Advanced Ocular Care, Refractive EyeCare and Optometry Times and has authored numerous articles for these as well as other professional publications. She is on the Scientific Board of Directors of Cynacon OCuSOFT and Noble Vision, as well as an advisor to a number of pharmaceutical companies.